NASHUA, N.H., Nov. 08, 2016 (GLOBE NEWSWIRE) -- iCAD (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Richard C. Christopher has been appointed Executive Vice President and Chief Financial Officer, effective December 5, 2016. Mr. Christopher has more than 25 years of financial management experience, including having served as CFO of two public companies with dermatology-related businesses. Upon Mr. Christopher's joining of the Company, interim Chief Financial Officer R. Scott Areglado, will resume his role as Vice President and Corporate Controller. "Rich's executive leadership and corporate finance experience with public companies in the dermatology market make him a strong addition to the iCAD leadership team," said Ken Ferry, CEO of iCAD. "He has a proven track record managing the financial activities for growth businesses, along with deep background in strategic planning and operations. This includes serving as CFO of DUSA Pharmaceuticals, Inc. a NASDAQ-listed specialty dermatology company, for more than 8 years, helping drive revenue from $1 million to more than $50 million with solid profitability prior to its sale for $230 million. We believe this makes Rich an excellent strategic fit with iCAD, particularly given that the dermatology eBx business represents our largest market opportunity. This combined with our breast tomosynthesis software, gives us two key growth drivers in 2017 and beyond. We look forward to working with Rich to refine and execute on our commercial activities and long-term strategic plan to deliver profitable growth and increased shareholder value." Mr. Christopher commented, "It is an exciting time to join iCAD - the Company is well positioned with leading technologies in its Cancer Therapy and Cancer Detection businesses and has significant potential to increase its market penetration. I look forward to working with the team to bring these technologies to more physicians and patients around the world."